Press Release: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced t

Dow JonesJun 4 07:00 ET

BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients

BioCryst Pharmaceuticals (BCRX) said Sunday an analysis showed that six patients with hereditary angioedema experienced a reduction in monthly attacks while taking oral, once-daily Orladeyo. BioCryst

MT NewswiresJun 3 03:46 ET

BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients With Normal C1-Inhibitor After Beginning ORLADEYO Treatment

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and functio

BenzingaJun 2 10:46 ET

BioCryst Pharmaceuticals(BCRX.US) Director Buys US$49,995.96 in Common Stock

$BioCryst Pharmaceuticals(BCRX.US)$ Director LEVIN ALAN G purchased 7,861 shares of common stock on May 30, 2024 at an average price of $6.36 for a total value of $49,995.96.Source: Announcement What

moomoo NewsMay 31 17:10 ET

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): When Will It Breakeven?

We feel now is a pretty good time to analyse BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) business as it appears the company may be on the cusp of a considerable accomplishment. BioCryst Pharmaceu

Simply Wall StMay 31 09:43 ET

BioCryst Pharmaceuticals(BCRX.US) Director Buys US$16,000 in Common Stock

$BioCryst Pharmaceuticals(BCRX.US)$ Director ASELAGE STEVE purchased 2,500 shares of common stock on May 24, 2024 at an average price of $6.4 for a total value of $16,000.Source: Announcement What is

moomoo NewsMay 29 17:01 ET